Woodline Partners LP Intra Cellular Therapies, Inc. Transaction History

Woodline Partners LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $52.2 Million - $64.2 Million	1,001,176 Added 519.94%	1,193,732 $62.2 Million
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $10.5 Million - $12.8 Million	192,556 New	192,556 $12.2 Million
Q4 2022 Feb 14, 2023	BUY	$44.07 - $54.45 $4.57 Million - $5.65 Million	103,704 Added 35.97%	392,030 $20.7 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $6.87 Million - $9.66 Million	160,984 Added 126.42%	288,326 $13.4 Million
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $5.48 Million - $8.36 Million	127,342 New	127,342 $7.27 Million
Q2 2021 Aug 16, 2021	SELL	$29.3 - $44.5 $8.62 Million - $13.1 Million	-294,285 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$30.8 - $39.51 $938,845 - $1.2 Million	-30,482 Reduced 9.39%	294,285 $9.99 Million
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $7.58 Million - $10.5 Million	324,767 New	324,767 $10.3 Million

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.